Other grades of this product :
| ACY-1215 Basic information |
| Product Name: | ACY-1215 | | Synonyms: | Rocilinostat (ACY-1215);2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide;ACY 63;2-(DiphenylaMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide;RICOLINOSTAT;ACY1215;ACY 1215;Rocilinostat, >=99%;5-Pyrimidinecarboxamide, 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-;2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide ACY 1215 | | CAS: | 1316214-52-4 | | MF: | C24H27N5O3 | | MW: | 433.5 | | EINECS: | | Product Categories: | Inhibitors;Inhibitor | | Mol File: | 1316214-52-4.mol |
| ACY-1215 Chemical Properties |
| Melting point | 189 - 191°C | | density | 1.239±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 9.47±0.20(Predicted) | | form | Solid | | color | White to Off-White |
| ACY-1215 Usage And Synthesis |
| Description | ACY-1215 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 5 nM). It is at least 10-fold less active against other HDACs in enzymatic assays. ACY-1215 shows synergistic activity with the proteasome inhibitor bortezomib against multiple myeloma (MM) cells, inducing protracted endoplasmic reticulum stress and apoptosis. ACY-1215 combined with proteasome inhibitors suppresses tumor growth and increases survival in mice with MM and mantle cell lymphoma xenografts. A multicenter phase I trial examining ACY-1215 combined with the E3 ligase inhibitor lenalidomide and dexamethasone in multiple myeloma found inhibition of HDAC6 in vivo. ACY-1215 also diminishes liver cyst development and fibrosis in a rat model of polycystic liver disease. | | Uses | This compound acts as a selective HDAC-6 (histone deacetylase) inihibitor. HDAC is linked to the transcription of DNA in cancers, including multiple myeloma (MM). |
| ACY-1215 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye